[¹⁸F]-Fluciclovine or [⁶⁸Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial.

ABSTRACT:

Background and objective

In EMPIRE-1, [¹⁸F]-fluciclovine positron emission tomography (PET) imaging to guide salvage radiotherapy (RT) for prostate cancer recurrence after prostatectomy resulted in an improvement in event-free survival (EFS) over conventional imaging alone. The aim of EMPIRE-2 was to explore the impact of RT dose escalation to sites of uptake on PET in comparison to EMPIRE-1.

Methods

EMPIRE-2 was a randomized trial of [¹⁸F]-fluciclovine versus [⁶⁸Ga]-PSMA-11 in a cohort of men with biochemical progression after prostatectomy and negative conventional imaging findings. After stratification, patients were randomized to RT guided by [¹⁸F]-fluciclovine PET (arm 1) or [⁶⁸Ga]-PSMA-11 PET (arm 2). PET findings

SUBMITTER: Jani AB 

PROVIDER: S-EPMC12879884 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature